All In Biotech

Investigational drug · Phase 3

Toludesvenlafaxine Hydrochloride Sustained-release

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Generalized Anxiety Disorder.

Phase 3

Last checked: Nov 20, 2026Latest source record: Jul 8, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

1

0 still active

All registered trials

6

Any phase or sponsor naming "Toludesvenlafaxine Hydrochloride Sustained-release"

First trial start

2023

Aug 4, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Toludesvenlafaxine Hydrochloride Sustained-release", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Generalized Anxiety Disorder

Approved drugs for the same conditions: Anxiety disorders · Psychiatry

Largest trials

Live from ClinicalTrials.gov: studies naming "Toludesvenlafaxine Hydrochloride Sustained-release" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 5 on PubMed

Also in development for Generalized Anxiety Disorder

  • SEP-363856UlotarontPhase 37 trials

    Otsuka · Generalized Anxiety Disorder, Schizophrenia, Major Depressive Disorder

  • ITI-1284JNJ-99245354Phase 36 trials

    Intra-Cellular Therapies, Inc. · Generalized Anxiety Disorder, Agitation Associated With Alzheimer's Dementia, Psychotic Disorders

  • DT120MM120, lysergide tartratePhase 34 trials

    Definium Therapeutics US, Inc. · Generalized Anxiety Disorder, Major Depressive Disorder

  • BuagafuranPhase 32 trials

    Beijing Union Pharmaceutical Factory Ltd · Generalized Anxiety Disorder

  • Buagafuran mimicPhase 32 trials

    Beijing Union Pharmaceutical Factory Ltd · Generalized Anxiety Disorder

  • ENX-102ENX-102 -dose, ENX-102 mid-dosePhase 23 trials

    Engrail Therapeutics INC · General Anxiety Disorder, Social Anxiety Disorder (SAD), Generalized Anxiety Disorder

  • RE104Phase 23 trials

    Reunion Neuroscience Inc · Adjustment Disorder, Generalized Anxiety Disorder, Postpartum Depression

  • CYB004Phase 21 trial

    Cybin IRL Limited · Generalized Anxiety Disorder

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.